<DOC>
	<DOC>NCT00345683</DOC>
	<brief_summary>The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives &amp; outcome measures of the booster phase. The objectives &amp; outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.</brief_title>
	<detailed_description>Hib-MenCY-TT = GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. The study will be conducted in a single blind manner up to 30 days after administration of the booster dose; the extended safety follow-up after the booster dose will be conducted in an unblinded manner. All subjects will receive Prevnar, M-M-R II and Varivax as study vaccines, preferencially co-administered with the booster dose of Hib-MenCY-TT/PedvaxHIB. Note: This protocol posting deals with the objectives &amp; outcome measures for the booster phase of the study. The objectives &amp; outcome measures for the primary phase are presented in a separate protocol posting (NCT00345579)</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects enrolled in the primary study (NCT00345579) are eligible for participating in the booster study Subjects should not be administered MMR II and Varivax if any of these criteria apply: History of measles, mumps, rubella or varicella. Previous vaccination against measles, mumps, rubella or varicella. Hypersensitivity to any component of the vaccines, including gelatin or neomycin. Patients receiving immunosuppressive therapy. Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. Individuals with primary and acquired immunodeficiency states. Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated. Individuals with active tuberculosis. Acute disease at time of booster vaccination</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>H. influenzae type B vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Vaccines, conjugate</keyword>
	<keyword>Meningococcal vaccines</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Comparative study</keyword>
	<keyword>Safety</keyword>
	<keyword>Humans</keyword>
</DOC>